Pfizer announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio Inc., a leading Chinese biopharmaceutical company, for the development, manufacturing and commerciali...

Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the develop...

Zinger Key Points - FDA advisors are planning to discuss if they should recommend COVID-19 vaccines for 2025-26 targeting the LP.8.1 subvariant. - Pfizer announces a licensing agreement with 3SBio to develop, manufacture and commercialize SSGJ-707 globally, excluding China. - Get 5 ‘Hidden Gem’…

Key takeaways Pfizer is een belangrijke samenwerking aangegaan met 3SBio, een toonaangevend Chinees biofarmaceutisch bedrijf. Deze exclusieve licentieovereenkomst verleent Pfizer wereldwijde rechten (met uitzondering van China) om SSGJ-707 te ontwikkelen, produceren en commercialiseren. SSGJ-707 is een bispecifiek antilichaam dat is ontworpen om PD-1 en VEGF te targeten. Het heeft veelbelovende initiële werkzaamheids- en veiligheidsgegevens laten […]

Pfizer and 3SBio have completed a licensing agreement that grants the US pharmaceutical giant worldwide rights to sell the Hong Kong-listed firm’s cancer drug, marking the largest deal ever for a single drug in China’s biotech industry. First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of...

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer arsenal via a potential $6 billion deal in May, of which $1.2 billion was paid up front.

Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, following the company's recently disclosed $6 billion licensing deal with 3SBio Inc. to develop and market the cancer treatment SSGJ-707. While a notable venture at face value, the deal has raised questions about Pfizer's continued collaboration with Summit Therapeutics (NASDAQ:

Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody SSGJ-707.

The agreement grants Pfizer exclusive development and commercialization rights outside China, with a $1.25 billion upfront payment and potential milestone payouts.

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Principaux renseignements Pfizer a conclu un partenariat important avec 3SBio, une société biopharmaceutique chinoise de premier plan. Cet accord de licence exclusif accorde à Pfizer les droits mondiaux (à l’exclusion de la Chine) pour développer, fabriquer et commercialiser le SSGJ-707. Le SSGJ-707 est un anticorps bispécifique conçu pour cibler PD-1 et VEGF. Il a montré […]

Pfizer (NYSE:PFE) has completed a global licensing agreement with 3SBio for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF for cancer treatment. The deal excludes China and involves a $1.25 billion payment plus a $100 million equity investment in 3SBio.SSGJ-707 has shown positive Phase 2 results in non-small cell lung cancer (NSCLC) and is being tested for other cancers. Pfizer plans to manufacture the drug in North Carolina and Kansas facilities, with upcoming Phase 3 global trials focusing on NSCLC and other solid tumors. The agreement includes an option for China rights for up to $150 million in additional payments.

Pfizer Inc. today announced it has entered into an exclusive global, ex- China, licensing agreement with 3 SBio, Inc., a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung...

Pfizer za miliardy dolarů získá globální licenci mimo Čínu na experimentální lék SSGJ-707, který se testuje pro léčbu emalobuněčného plicního karcinomu, metastatického kolorektálního karcinomu a gynek...

Exclusive license to promising investigational cancer immunotherapy complements and strengthens Pfizer’s innovative Oncology portfolio NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed …

Not every billion dollar biotech deal is created equal. While most eyes were fixed on the usual suspects – Summit,…